Rigel Pharmaceuticals (RIGL) Getting Somewhat Positive Press Coverage, Report Finds

News headlines about Rigel Pharmaceuticals (NASDAQ:RIGL) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rigel Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.1515325786328 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have effected Accern’s scoring:

Rigel Pharmaceuticals (NASDAQ:RIGL) traded down $0.07 during mid-day trading on Friday, reaching $3.82. The company had a trading volume of 800,785 shares, compared to its average volume of 1,211,248. Rigel Pharmaceuticals has a 12 month low of $1.94 and a 12 month high of $4.33.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. The business had revenue of $0.90 million for the quarter. Rigel Pharmaceuticals had a negative return on equity of 102.26% and a negative net margin of 354.14%. The company’s revenue for the quarter was down 76.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.24) earnings per share. equities research analysts anticipate that Rigel Pharmaceuticals will post -0.58 earnings per share for the current year.

RIGL has been the topic of a number of analyst reports. BMO Capital Markets restated a “buy” rating and set a $5.00 target price on shares of Rigel Pharmaceuticals in a research report on Monday, October 2nd. Jefferies Group LLC restated a “buy” rating and set a $5.00 target price on shares of Rigel Pharmaceuticals in a research report on Tuesday, September 5th. Zacks Investment Research upgraded Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Saturday, November 11th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Rigel Pharmaceuticals in a research report on Monday, November 6th. Finally, ValuEngine cut Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $5.31.

TRADEMARK VIOLATION WARNING: “Rigel Pharmaceuticals (RIGL) Getting Somewhat Positive Press Coverage, Report Finds” was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.truebluetribune.com/2017/11/18/rigel-pharmaceuticals-rigl-getting-somewhat-positive-press-coverage-report-finds.html.

In other news, CFO Ryan D. Maynard sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $3.90, for a total transaction of $390,000.00. Following the transaction, the chief financial officer now directly owns 100,000 shares in the company, valued at approximately $390,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 5.21% of the company’s stock.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Insider Buying and Selling by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply